Faeth Therapeutics, Inc. Additional Paid in Capital, Common Stock
Faeth Therapeutics, Inc. (FTH) had Additional Paid in Capital, Common Stock of $642.40 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-04
- 2026-06-30: Additional Paid in Capital, Common Stock $642.40M.
- 2026-03-31: Additional Paid in Capital, Common Stock $316.11M.
- 2025-12-31: Additional Paid in Capital, Common Stock $301.73M.
- 2025-09-30: Additional Paid in Capital, Common Stock $301.43M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $642.40M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $316.11M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $301.73M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $301.43M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $301.18M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $300.91M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $300.45M 10-K · filed 2026-03-30 | $300.45M 10-K · filed 2025-03-28 |
| 2024-09-30 | $300.04M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $299.31M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $298.50M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $297.00M 10-K · filed 2025-03-28 | |
| 2023-09-30 | $295.88M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $297.10M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $303.64M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $302.20M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $300.75M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $299.27M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $297.81M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $296.05M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $295.11M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $293.38M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $291.63M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $55.97M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |